Protocol
One avocado a day for visceral fat
In the Habitual Diet and Avocado Trial, 1,008 adults with a large waist ate one avocado a day or their usual diet for 6 months.
Grade D, tested: a human randomized trial looked for a benefit on the endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. graded and did not find one. How to read a grade →
At a glance
A large trial gave over a thousand adults with big waists one avocado a day for six months. Others kept eating as usual. Scans then measured the deep fat around their organs. That fat did not change in the avocado group compared with the others. Other heart risk measures changed little.
- What was measured
- Visceral fat by MRI after 6 months.
- How big
- No difference in visceral fat between groups.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 35861827.
- Who it applies to
- Adults with an elevated waist circumference.
- Safety
- None identified.
- Compared with
- Usual diet without the avocado.
- Certainty
- Grade D, resting on: One large multicenter randomized trial, primary endpoint The one outcome a trial names in advance as its main test. Results on other outcomes carry less weight. not met.
- What would change this grade
- Could rise to C with: Randomized trial of avocado replacing saturated fat sources. Who: Adults with raised LDL Low-density lipoprotein cholesterol, the cholesterol fraction most closely tied to plaque in the arteries.. Measured: LDL cholesterol. Length: At least 3 months.
- Cost
- No price recorded yet.
- Sources
- 1 study cited on this record, listed under Sources.
- For clinicians
- A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
In the Habitual Diet and Avocado Trial, 1,008 adults with a large waist ate one avocado a day or their usual diet for 6 months. Visceral fat measured by MRI did not differ between groups, and risk factors changed little. The stated endpoint was tested and not met, so the letter is D on Route 2 Human randomized trials have been run and did not show benefit on the stated outcome. One of the two routes to the lowest letter on EBL's scale..
Why this letter
Why this gradeGrade D, tested, no benefit. The reasoning, and what the grade does not cover.
Grade D on Route 2 for visceral fat. A 1,008-person randomized trial tested one avocado a day for 6 months and found no difference in visceral fat by MRI (Lichtenstein et al., 2022; PMID 35861827).
WHAT THIS GRADE DOES NOT COVERLDL cholesterol, a secondary finding not graded here, and avocado in place of other foods rather than added to the usual diet.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Who responds: this record's trial reading reports no subgroup that identifies who responds.
Evidence notes: randomized trial
Endpoint graded: Visceral fat by MRI (surrogate)
Last reviewed: November 2026
The trial that would change this grade.
A positive trial of this shape would move this entry to C.
Why the current trials fall short
A different use, avocado in place of other fats, has not been graded.
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Avocado among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Dose, form and timing
None; the trial found no effect on visceral fat.
Safety
No safety data. Each caution on this record, sorted by what it rests on.
None recorded.
None recorded.
None recorded.
None recorded.
No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.
Grade history
How this letter has changedLatest: No. 448 · November 2026 · First graded.
New record in the food section. In the Habitual Diet and Avocado Trial, 1,008 adults with a large waist ate one avocado a day or their usual diet for 6 months. Visceral fat measured by MRI did not differ between groups, and risk factors changed little. The stated endpoint was tested and not met, so the letter is D on Route 2.PMID 35861827
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
The evidence, in fullOne paper, linked to its PubMed record.
Lichtenstein et al. (J Am Heart Assoc, 2022; PMID 35861827): HAT, multicenter randomized parallel trial, 1,008 free-living adults with elevated waist circumference, one large avocado a day against habitual diet for 6 months; visceral adipose tissue by MRI not different (mean difference 0.017 L, 95% CI -0.024 to 0.058); no significant differences in secondary outcomes of liver fat and other measures.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
avocado*[tiab] AND randomized controlled trial[pt]PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the search behind this grade has been added to PubMed since November 2026.
Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.
- Lichtenstein et al., 2022, J Am Heart Assoc (PMID 35861827): PubMed lists no funder for this trial.
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →